Ipamorelin Favorable Safety Profile vs. GHRP-6 (No Cortisol or Prolactin Elevation)
Dr. Jones contrasts ipamorelin favorably against older growth hormone secretagogues, specifically GHRP-6, noting that ipamorelin does not spike cortisol or prolactin. This is presented as a clinically meaningful advantage in the GLP-1 context where caloric restriction already elevates cortisol as a catabolic mechanism. The implication is that GHRP-6 would worsen the cortisol-driven muscle catabolism already present in GLP-1 users, while ipamorelin avoids this. The comparison is based on the speaker's clinical knowledge rather than a cited head-to-head trial.